Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Lorcaserin for Preventing Weight Gain Among Smokers

9. maj 2017 opdateret af: Ryan T. Hurt, M.D., Ph.D., Mayo Clinic

Lorcaserin for Preventing Weight Gain Among Smokers Receiving Varenicline: A Pilot Study

This will be an open label clinical trial with all subjects receiving both lorcaserin and varenicline with a primary aim of reducing post cessation weight gain.

Studieoversigt

Status

Afsluttet

Detaljeret beskrivelse

This will be an open label clinical trial with all subjects receiving both lorcaserin and varenicline. The investigators will obtain preliminary data on the efficacy of lorcaserin (10 mg twice daily) for 12 weeks in 20 adult weight-concerned cigarette smokers with a BMI of 27 to 40 simultaneously receiving 12 weeks of open-label varenicline and a behavioral intervention to assist with stopping smoking. Secondary aims will be weight, waist circumference, and smoking cessation.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

20

Fase

  • Fase 2
  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Minnesota
      • Rochester, Minnesota, Forenede Stater, 55905
        • Mayo Clinic in Rochester

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 65 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. ≥18 years and ≤65 years of age;
  2. smoked ≥10 cigarettes/day for the past 6 months;
  3. BMI of 27-40 kg/m2;
  4. resides within the Olmsted County area;
  5. motivated to stop smoking;
  6. weight concerned as shown with the Weight Concern Scale;
  7. able to participate fully in all aspects of the study;
  8. understood and signed the study informed consent.

Exclusion Criteria:

  1. current nonspecific suicidal thoughts or a lifetime history of a suicidal attempt (defined by the Columbia-Suicide Severity Rating Scale [C-SSRS] as a "potentially self-injurious act committed with at least some wish to die, as a result of act.");
  2. current moderate or severe depression as assessed by a score of ≥16 on the Center for Epidemiologic Studies-Depression (CES-D);
  3. a lifetime history of bipolar disorder or schizophrenia;
  4. use of anti-psychotic medication within the past 30 days;
  5. use of weight-loss medications within the past 30 days or current participation in a program specifically designed to help with weight loss;
  6. weight fluctuations of 20 pounds or more in the past 6 months (self-report);
  7. use of any treatments for tobacco dependence within the past 30 days;
  8. use of an investigational drug within the past 30 days;
  9. recent history (past 3 months) of abuse of or dependence on a substance other than tobacco;
  10. current use of benzodiazepines, narcotics, anti-epileptics, or other medications known to interact with lorcaserin (see human subjects section);
  11. current use of triptans, monoamine oxidase inhibitors, selective serotonin reuptake inhibitors (SSRIs), selective serotonin-norepinephrine reuptake inhibitors (SNRIs), dextromethorphan, tricyclic antidepressants (TCAs), bupropion, lithium, tramadol, tryptophan, and St. John's Wort, or any other medication known to involve the serotonergic neurotransmitter system (see human subjects section);
  12. uncontrolled hypertension (systolic >160 mm Hg and/or diastolic >100 mm Hg) documented on 2 separate occasions;
  13. clinically significant acute or chronic progressive or unstable neurologic, hepatic, renal, cardiovascular, respiratory, or metabolic disease;
  14. current use of medications known to interact with varenicline or lorcaserin;
  15. another household member or relative participating in the study;
  16. Known Diabetes;
  17. a known allergy to varenicline or lorcaserin;
  18. have taken antibiotics within the past 3 months.
  19. Women who are pregnant or lactating, or who are of childbearing potential and are likely to become pregnant during the medication phase but are not willing to use a reliable form of contraception, will also be excluded. Reliable forms of contraception include oral contraception, diaphragm or condom (with spermicide), injections, intrauterine device, surgical sterilization, and abstinence.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Varenicline + Lorcaserin
Open label all subjects receive both Varenicline and Lorcaserin
All subjects receive Varenicline
Andre navne:
  • Chantix
All subjects receive Lorcaserin
Andre navne:
  • Belviq

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Post Cessation Weight Change
Tidsramme: 12 weeks
change in weight from baseline to week 12
12 weeks

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Waist Circumference
Tidsramme: 12 Weeks
Change in waist circumference from baseline to week 12
12 Weeks
Smoking Abstinence Rates
Tidsramme: 12 weeks
prolonged smoking abstinence at week 12
12 weeks
BMI
Tidsramme: 12 weeks
Change in BMI from baseline to week 12
12 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: Ryan Hurt, MD, PhD, Mayo Clinic

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. september 2013

Primær færdiggørelse (Faktiske)

1. december 2015

Studieafslutning (Faktiske)

1. december 2015

Datoer for studieregistrering

Først indsendt

13. marts 2015

Først indsendt, der opfyldte QC-kriterier

18. marts 2015

Først opslået (Skøn)

19. marts 2015

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

6. juni 2017

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

9. maj 2017

Sidst verificeret

1. maj 2017

Mere information

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Varenicline

Abonner